Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant Ewing's sarcoma

Cancer Gene Therapy

Volumn 13, Issue 10, 2006, Pages 948-957

  Jia, S F ^a   Duan, X ^a   Worth, L L ^a   Guan, H ^a   Kleinerman, E S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Ad.mIL 12; Distant metastases; Ewing's sarcoma; Intratumor injection

Indexed keywords

ADENOVIRUS VECTOR; FAS LIGAND; GALACTOSIDASE; INTERLEUKIN 12; PROTEIN P35; PROTEIN P40; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; EWING SARCOMA; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BASE SEQUENCE; BONE NEOPLASMS; CELL LINE; DNA PRIMERS; HUMANS; INJECTIONS, INTRALESIONAL; INTERLEUKIN-12; MICE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA, EWING'S;

ADENOVIRIDAE; ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 33748576913     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700968     Document Type: Article

References (33)

1. Dorfman HD, Czerniak B. Bone cancers. Cancer 1995; 75(Suppl): 203-210.
2. Ginsberg JP, Woo SY, Johnson ME, John Hicks M, Horowitz ME. Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In: Pizzo PA, Poplack DG (eds). Principles and Practice of Pediatric Oncology. Lippincott Williams & Wilkins Publishers: Philadelphia, 2002, pp 973-1016.
3. Shankar AG, Ashley S, Craft AW, Pinkerton CR. Outcome after relapse in an unselected cohort of children and adolescents with Ewing's sarcoma. Med Pediatr Oncol 2003; 40: 141-147.
4. Bacci G, Ferrari S, Longhi A, Donati D, De Paolis M, Forni C. Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 2003; 14: 1654-1659.
5. Rodriguez-Galindo C, Billupa CA, Kun LE, Rao BN, Pratt CB, Merchant TE. Survival after recurrence of Ewing's tumors: the St Jude children's Research Hospital experience, 1979-1999. Cancer 2002; 94: 561-569.
6. Stern AS, Podlaski FJ, Hulmes JD, Pan YC, Quinn PM, Wolitzsky AG et al. Purification to homogeneity and partial characterization of cytotoxic maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 1990; 87: 6808-6812.
7. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chen S et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokines with multiple biological effects on human lymphocytes. J Exp Med 1989; 170: 827-845.
8. Rabinowich H, Herberman RB, Whiteside TL. Differential effects of IL-12 and IL-12 on expression and function of cellular adhesion molecules on purified human natural killer cells. Cell Immunol 1993; 152: 481-498.
9. Coughlin CM, Salhan KE, Wysocka M, Aruga E, Kurzawa H, Chang AE et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Investig 1998; 101: 1441-1452.
10. Chen L, Chen D, Bloack E, O'Donnel M, Kufe DW, Clinton SK. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNA for the IL-12 heterodimer and its inhibition by the p40 subunit homodimer. J Immunol 1997; 159: 351-359.
11. Siders W, Wright P, Hixon J, Alvord W, Back T, Wiltrout R et al. Cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus. J Immunol 1998; 160: 5465-5474.
12. Brunda MJ, Luistro RB, Warrier RR, Wright RB, Hubbard BR, Murphy M et al. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med 1993; 178: 1223-1230.
13. Motzer RJ, Rakhat A, Schwatz LH, Olencki T, Malone TM, Sandstrom K et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 1998; 4: 1183-1191.
14. Bajetta E, Del Vecchio M, Mortarini R, Nadeau R, Rakhit A, Rimassa L et al. Pilot study of subcutaneous human recombinant interleukin-12 in metastatic melanoma. Clin Cancer Re 1998; 4: 75-85.
15. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997; 3: 409-417.
16. Worth LL, Jia S-F, Zhou Z, Chen L, Kleinerman ES. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin Cancer Res 2000; 6: 3713-3718.
17. Jia S-f, Worth LL, densmore CL, Xu B, Zhou Z, Kleinerman ES. Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethyleneimine vector. Cancer Gene Ther 2002; 9: 260-266.
18. Lafleur EA, Jia S-F, Worth LL, Zhou Z, Owen-Schaub LB, Kleinerman ES. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. Cancer Res 2001; 6: 4066-4071.
19. Lee J-K, Sayer TJ, Brooks AD, Back TC, Young HA, Komschlies L. IFN-γ-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells. J Immunol 2000; 164: 231-239.
20. Peng SL, Robert ME, Hayday AC, Craft J. A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J Exp Med 1996; 184: 1149-1154.
21. Schoenhaut DS, Chua AO, Wolitzky AG, Quinn PM, Dwyer CM, McComas W et al. Cloning and expression of murine IL12. J Immunol 1992; 148: 3433-3440.
22. Mu J, Zou J-P, Yamamoto N, Tsutsui T, Tai X-G, Kobayashi M. Administration of recombinant interleukin 12 prevent outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res 1995; 55: 4404-4408.
23. Cavallo F, Carlo ED, Butera M, Verrua R, Colombo MP, Musiani P et al. Immune events associated with the cure of established tumor and spontaneous metastases by local and systemic interleukin 12. Cancer Res 1999; 59: 414-421.
24. Shrayer DP, Bogaars H, Cole B, Wolf SF, Wanebo HJ. Capacity of murine IL-12 to inhibit the development of primary melanoma tumors and to prevent lung metastases in the melanoma-challenged mice. J Exp Ther Oncol 2002; 2: 93-99.
25. Oshikawa K, Rakhmilevich AL, Shi F, Sondel PM, Yang N-S, Mahvi DM. Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effect equivalent to local gene transfer. Human Gene Ther 2001; 12: 149-160.
26. Cohen J. IL-12 deaths: Explanation and puzzle. Science (Washington DC) 1995; 270: 908.
27. Leonard JP. Effect of single-dose interleukin-12 exposure on interleukin-12 associated toxicity and interferon-g production. Blood 1997; 90: 2541-2548.
28. Itoh N, Yonahara S, Ishii A, Yonahara M, Mizushima S, Sameahima M. The Polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233-243.
29. Zhang S, Zeng G, Kao C, Gardner T, Aweeney C, Yang N-S et al. Fas-Fas ligand signaling pathway mediates an interleukin-12-induced rejection of a murine prostate tumor system. Prostate 2002; 53: 69-76.
30. Friesen C, Herr I, Krammer PH, Debatin K-M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2: 574.
31. Fulda S, Los M, Friesen C, Debatin K-M. Chemosensitivity of solid tumor cells in vitro is related to activation of the CS95 system. Int J Cancer 1998; 76: 105-114.
32. Weller M, Winter S, Schmidt C, Esser P, Fontana A, Dichgans J. Toposoimerase-1 inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and β-lapachone. Int J Cancer 1997; 73: 707-714.
33. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT. Sensitization of cancer cells treated with cytotoxic drug to Fas-mediated cytotoxicity. J Nat Cancer Inst 1997; 89: 783-789.